- $4.98m
- $5.20m
- $15.71m
- 28
- 51
- 33
- 30
Annual income statement for CV Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 24.4 | 20 | 16.2 | 16 | 15.7 |
| Cost of Revenue | |||||
| Gross Profit | 11 | 8.82 | 5.55 | 7.08 | 7.17 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 47 | 35.5 | 22.9 | 12.6 | 17.9 |
| Operating Profit | -22.6 | -15.5 | -6.72 | 3.36 | -2.19 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.6 | -15.6 | -8.26 | 3.1 | -2.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22.3 | -15.6 | -8.21 | 3.1 | -2.39 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.3 | -15.6 | -8.21 | 3.1 | -2.39 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -22.3 | -15.6 | -9.13 | 3.1 | -2.39 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.223 | -0.126 | -0.058 | 0.022 | -0.011 |